Shares of Dianthus Therapeutics Inc. (DNTH) are soaring 5.11% in Tuesday's pre-market trading session, following a positive analyst report from Evercore ISI. The biotech company's stock has caught investors' attention as it demonstrates significant upward momentum.

The surge comes after Evercore ISI analyst Gavin Clark-Gartner reiterated a Buy rating on Dianthus Therapeutics stock. In a report released on Monday, Clark-Gartner maintained an optimistic outlook for the company, setting a price target of $50 for DNTH shares. This target suggests substantial upside potential from the stock's current trading levels.

Analyst ratings often play a crucial role in shaping investor sentiment, particularly for biotech companies like Dianthus Therapeutics. The maintained Buy rating and the ambitious price target indicate Evercore ISI's confidence in the company's pipeline and future prospects. As investors digest this positive assessment, it appears to be driving increased interest and buying activity in DNTH stock during the pre-market session.